Danicopan’s FDA approval: a breakthrough in the treatment of paroxysmal nocturnal hemoglobinuria
Year: 2025
Type: article
Abstract: The FDA’s approval of Danicopan (Vodeya) on 1 April 2024, represents a significant advancement in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). As the first oral serine protease factor D inhibitor, Danicopan complements existing C5 inhibitors by addressing both intravascular and extravascular hemolysis. In the phase 3 ALPHA trial, Danicopan as an add-on therapy to ravulizumab or eculizumab significantly improved hemoglobin levels, with a least squares mean difference of 2.44 g/dL compared to placebo (P < 0.0001). Key advancements include its ability to reduce transfusion dependency, improve patient quality of life, and its convenient oral administration compared to intravenous therapies. Potential side effects include severe headache, fever, blurred or tunnel vision, sudden dizziness, and an increased risk of infections by encapsulated organisms, along with rare adverse events such as elevated liver enzymes and neutropenia. Danicopan’s approval fills a critical therapeutic gap, offering a transformative approach to managing PNH.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4408035458